Amgen Inc. Disclosure on Geographic Areas, Revenue from External Customers Attributed to Foreign Countries (Deprecated 2013-01-31)
Amgen Inc. (AMGN) reported Disclosure on Geographic Areas, Revenue from External Customers Attributed to Foreign Countries (Deprecated 2013-01-31) of $3.85 billion for the 12-month period ending 2012-12-31, per its 10-K filed 2013-02-27.
Discontinued › Income Statement › Other Income
us-gaap:EntityWideDisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToForeignCountries · last filed 2013-02-27
- Amgen Inc. disclosure on geographic areas, revenue from external customers attributed to foreign countries (deprecated 2013-01-31) for fiscal 2012 was $3.85B, a 7.03% increase from fiscal 2011.
- Amgen Inc. disclosure on geographic areas, revenue from external customers attributed to foreign countries (deprecated 2013-01-31) for fiscal 2011 was $3.60B, a 5.27% increase from fiscal 2010.
- Amgen Inc. disclosure on geographic areas, revenue from external customers attributed to foreign countries (deprecated 2013-01-31) for fiscal 2010 was $3.42B, a 6.09% increase from fiscal 2009.
- Amgen Inc. disclosure on geographic areas, revenue from external customers attributed to foreign countries (deprecated 2013-01-31) for fiscal 2009 was $3.22B, a 0.31% decline from fiscal 2008.
| Period end | Disclosure on Geographic Areas, Revenue from External Customers Attributed to Foreign Countries (Deprecated 2013-01-31) 12 month |
|---|---|
| 2012-12-31 | $3.85B 10-K · filed 2013-02-27 |
| 2011-12-31 | $3.60B 10-K · filed 2013-02-27 |
| 2010-12-31 | $3.42B 10-K · filed 2013-02-27 |
| 2009-12-31 | $3.22B 10-K · filed 2012-02-29 |
| 2008-12-31 | $3.23B 10-K · filed 2011-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |